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Abstract 
Background: Chronic fatigue syndrome (CFS) is a common and disabling disorder, and a major threat against 
adolescent health. The pathophysiology is unknown, but alteration of neuroendocrine control systems might be a 
central element, resulting in attenuation of the hypothalamus–pituitary–adrenalin (HPA) axis and enhancement of the 
sympathetic/adrenal medulla (SAM) system. This study explored differences in neuroendocrine control mechanisms 
between adolescent CFS patients and healthy controls, and whether characteristics of the control mechanisms are 
associated with important clinical variables within the CFS group.
Methods: CFS patients 12–18 years of age were recruited nation-wide to a single referral center as part of the Nor-
CAPITAL project. A broad case definition of CFS was applied. A comparable group of healthy controls were recruited 
from local schools. A total of nine hormones were assayed and subjected to network analyses using the ARACNE 
algorithm. Symptoms were charted by a questionnaire, and daily physical activity was recorded by an accelerometer.
Results: A total of 120 CFS patients and 68 healthy controls were included. CFS patients had significantly higher 
levels of plasma norepinephrine, plasma epinephrine and plasma FT4, and significantly lower levels of urine cortisol/
creatinine ratio. Subgrouping according to other case definitions as well as adjusting for confounding factors did not 
alter the results. Multivariate linear regression models as well as network analyses revealed different interrelations 
between hormones of the HPA axis, the SAM system, and the thyroid system in CFS patients and healthy controls. 
Also, single hormone degree centrality was associated with clinical markers within the CFS group.
Conclusion: This study reveals different interrelation between hormones of the HPA axis, the SAM system, and the 
thyroid system in CFS patients and healthy controls, and an association between hormone control characteristics and 
important clinical variables in the CFS group. These results add to the growing insight of CFS disease mechanisms.
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Background
Chronic fatigue syndrome (CFS) is characterized by 
unexplained, long-lasting, disabling fatigue and exertion 
intolerance, accompanied by pain, cognitive impair-
ments, orthostatic problems and other symptoms [1]. 
CFS is a major cause of disability among adolescents, and 
may have detrimental effects on psychosocial and aca-
demic development [2, 3], as well as family functioning 
[4]. Adolescent CFS prevalence is estimated at 0.1–1.0 % 
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The pathophysiology of CFS is poorly understood, but 
several lines of evidence suggest subtle alteration of neu-
roendocrine control mechanisms. Attenuation of the 
hypothalamus-pituitary-adrenal axis (HPA axis) is docu-
mented in adult [7] as well as adolescent CFS patients 
[8–10]. Recent findings indicate an association between 
HPA axis function and the experience of post-exertional 
malaise (a hallmark of the CFS phenotype) [11], as well 
as normalization of the HPA axis function during recov-
ery [9, 11]. In addition, previous adolescent studies report 
enhanced sympathetic cardiovascular nervous activity as 
well as increased levels of epinephrine and norepinephrine 
in CFS [10, 12, 13]. The underlying reason for altered auto-
nomic cardiovascular control might be changes in brain-
stem reflex mechanisms [14]. Again, recovery from clinical 
symptoms seems to parallel an improvement of sympa-
thetic nervous function [15]. A limited number of studies 
have addressed thyroid function in CFS; however, Moork-
ens and co-workers reported increased TSH and normal 
free thyroxine levels [16]. Taken together, these observa-
tions indicate that altered neuroendocrine control mecha-
nisms might be at the core of CFS pathophysiology, in line 
with contemporary theoretical disease models [17, 18].
Dynamic function tests remain the “gold standard” 
for exploring neuroendocrine control mechanism, but 
are often not feasible in large patient cohorts. In addi-
tion, such tests often imply infusion of biologically active 
substances, causing an ethical dilemma in participants 
that cannot provide fully informed consent. Modern 
techniques of systems biology, such as network analy-
ses, might provide an alternative approach. Fuite and 
co-workers demonstrated that adult CFS patients, as 
compared to healthy controls, display profound re-mod-
eling of neuroendocrine and immune network, suggest-
ing altered control mechanisms [19]. These interesting 
results from a small-scale exploratory study have to the 
best of our knowledge never been reproduced in a larger 
data set, nor have similar analyses been undertaken in 
adolescent CFS patients.
Thus, the aim of this study was to explore differences 
in neuroendocrine control mechanisms between adoles-
cent CFS patients and healthy controls by studying the 
interrelation between hormones of the HPA axis, the 
sympathetic/adrenal medulla (SAM) system, and the thy-
roid system in the two groups. Furthermore, we explored 
whether characteristics of the control mechanisms are 




The Department of Paediatrics at Oslo University Hospi-
tal is a national referral center for young CFS patients. For 
this study, all hospital paediatric departments in Norway 
(n = 20), as well as primary care paediatricians and gen-
eral practitioners, were invited to refer CFS patients aged 
12–18 years consecutively to our department. Details of 
the recruitment procedure are reported elsewhere [10]. 
Patients considered eligible to this study were summoned 
to a clinical encounter at our study center after which a 
final decision on inclusion was made.
In agreement with clinical guidelines [20], we applied 
a ‘broad’ case definition of CFS, requiring 3  months of 
unexplained, disabling chronic/relapsing fatigue of new 
onset. We did not require that patients meet any other 
accompanying symptom criteria, in contrast to the case 
definitions from the International Chronic Fatigue Syn-
drome Study Group at the Centers for Disease Control 
and Prevention (commonly referred to as the Fukuda-
definition) [21], and the Canadian Consensus Criteria 
(the Canada 2003-definition) [22]. However, the valid-
ity of these definitions has not been established [23], 
and empirical findings raise concerns about the valid-
ity, in particular among adolescents [24–26]. In the pre-
sent study, subgrouping of the participants according to 
the Fukuda-definition and Canada 2003-definition was 
performed post hoc, based on questionnaire results (cf. 
below).
Healthy controls
A group of healthy controls with a comparable distribu-
tion of gender and age were recruited from local schools. 
Controls were not matched to cases on any variable. No 
chronic disease and no regular use of pharmaceuticals 
were allowed.
Study design and ethics
This study is part of the NorCAPITAL-project (The 
Norwegian Study of Chronic Fatigue Syndrome in Ado-
lescents: Pathophysiology and Intervention Trial; Clini-
calTrials ID: NCT01040429), and details of study design 
have been provided elsewhere [10]. Briefly, data were 
collected in the period March 2010 until October 2012. 
A 1-day in-hospital assessment included clinical exami-
nation and blood sampling, and always commenced 
between 7.30 and 9.30 a.m. All participants were 
instructed to abstain from tobacco products and caffeine 
at least 48 h in advance, to fast overnight and to bring a 
morning spot urine sample in a sterile plastic container. 
They were also instructed to apply an ointment contain-
ing the local anesthetic lidocaine (Emla®) on the skin 
in the antecubital area 1  h prior to the blood sampling. 
After at least 5  min supine rest in calm surroundings, 
blood samples were obtained in a fixed sequence from 
antecubital venous puncture. Following the in-hospital 
assessment, daily physical activity was monitored during 
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seven consecutive days using an accelerometer, and a 
self-administered questionnaire was completed. After 
completion of baseline assessment, the CFS patients 
were subjected to a randomized controlled trial of low-
dose clonidine featuring follow-up controls at week 8 and 
week 30 [10]; this paper, however, report baseline result 
only.
NorCAPITAL has been approved by the Norwegian 
National Committee for Ethics in Medical Research and 
the Norwegian Medicines Agency. Written informed 
consent was obtained from all participants, and from 
parents/next-of-kin if required.
Questionnaire
In accordance with a reliable and valid CFS symptom 
inventory for adults [27], we have developed a CFS symp-
tom inventory for adolescents, assessing the frequency of 
24 common symptoms during the preceding month [10]. 
Each symptom is rated on a 5-point Likert scale, rang-
ing from ‘never/rarely present’ to ‘present all of the time’. 
The inventory includes accompanying symptom of the 
Fukuda-definition and Canada 2003-defintion, facilitat-
ing post hoc subgrouping of CFS patients.
The Chalder Fatigue Questionnaire (CFQ) [28] is 
regarded a reliable and valid measure in CFS research 
among adolescents [29]. In this study, the CFQ total sum 
score is applied (i.e., the sum across all 11 CFQ items, 
each of which is scored on a 0–3 Likert scale). Total range 
is from 0 to 33; higher scores imply more severe fatigue.
The Mood and Feelings Questionnaire (MFQ) has been 
thoroughly validated in children and adolescents [30], 
and is also shown to have good reliability [31]. MFQ con-
sists of 34 items, each scored on a 0–2 Likert scale; thus, 
the total sum score is from 0 to 68. A score ≥20 implies 
presence of depressive symptoms to a degree that sug-
gests a mood disorder.
The questionnaire also charted other relevant variables, 
such as disease duration (in the CFS group) and men-
strual cycle characteristics (in females).
Daily physical activity
Accelerometers have been successfully applied in pre-
vious CFS studies [32, 33]. In this study, we used the 
activPAL accelerometer device (PAL Technologies Ltd, 
Glasgow, Scotland) which provides inter device reliable 
and valid data on step number and cadence as well as 
time spent on walking, standing and sitting/lying during 
everyday activities [34, 35]. A recording period of seven 
consecutive days was selected.
Data from the recording units was transferred to a 
computer running producer developed software. For 
each participant, all recording epochs were carefully 
and independently reviewed by two of the authors (DS 
and EF), and the mean number of steps per day was cal-
culated for all recording epochs. Details on the activity 
recording procedure have been reported elsewhere [10].
Laboratory assays
The blood samples for plasma norepinephrine (NE) 
and epinephrine (E) analyses were obtained in vacu-
tainer tubes treated with ethylene glycol tetraacetic acid 
(EGTA)–Glutathione. The samples were placed on ice for 
approximately 30  min; thereafter, plasma was separated 
by centrifugation (3000 rpm, 15 min, 4 °C) and frozen at 
−80 °C until assayed. Samples were analyzed for plasma 
NE and E by high-performance liquid chromatography 
(HPLC) with a reversed-phase column and glassy car-
bon electrochemical detector (Antec, Leyden Deacade II 
SCC, Zoeterwoude, The Netherlands) using a commer-
cial kit (Chromsystems, München, Germany) [36, 37]. 
The intra- and interassay coefficient of variation (CV) 
were 3.9 and 10.8  %, respectively. The detection limit 
was 5.46 pm. Plasma cortisol as well as plasma levels of 
adrenocorticotrophic hormone (ACTH), thyroid-stim-
ulating hormone (TSH), and free thyroxine (FT4) were 
determined by routine assays at the accredited laboratory 
at Oslo University Hospital, Norway.
Urine samples for NE and E analyses were acidified 
to pH 2.5 immediately after collection, and thereafter 
stored at 2–8 °C until assayed. Urine treated this way is 
stable at least 5  days. The same HPLC protocol as for 
plasma measurement was used for the measurement of 
urin NE/E. The intra- and interassay coefficient of varia-
tion (CV) for urine were 3.9 and 5.2 %, respectively. For 
determination of urine free cortisol (non-conjugated 
cortisol), the urine samples were extracted with ether 
to avoid interference from other steroids, and thereaf-
ter assayed by solid phase competitive luminescence 
immunoassay (LIA) (type Immulite® 2000, Siemens 
Healthcare Diagnostics, NY, USA) [38]. Intra- and inte-
rassay CV were <10  %. The urine levels of creatinine 
were analyzed using standard automatic analyzer tech-
niques at the accredited laboratory at Oslo University 
Hospital, Norway. All urine analyses were performed 
consecutively.
Statistical analysis
As the CFS patients were included in a randomised con-
trolled trial, individual data from follow-up consultations 
(when available) were used for imputation of missing data 
at baseline. For the remaining missing data (appr. 1 % of 
total) we used single imputation, as the results aggrega-
tion step required by a multiple imputation procedure 
would be challenging in the context of network analysis 
(cf. below), and only marginally improve the efficiency of 
the estimation procedure [39].
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Statistical analyses were carried out in SPSS (SPSS Inc., 
Chicago, Illinois, USA) and R [40]. Patients with CFS 
were compared with healthy controls by applying Student 
t, Mann–Whitney, χ2, or Fisher exact tests as appropriate. 
CFS patients adhering to the Fukuda-definition and the 
Canada 2003-definition were compared to the healthy 
controls in the same way. Multivariate linear regression 
analyses were applied to adjust across-group p values for 
the possible confounding effects of gender, age, BMI and 
depressive symptoms. The level of significance was set at 
0.05.
Relationships between hormones were first explored 
in separate multivariate linear regression models for CFS 
patients and healthy controls, respectively, and thereafter 
by network analyses in the two groups (cf. below). As pre-
vious studies have been mainly concerned with altered 
control of the HPA axis and SAM-system, we focused the 
analyses on these two systems. The across-group com-
parisons of network parameters imply a large number of 
statistical tests, requiring adjustment of the significance 
level according to the Bonferroni method.
The networks of associations among hormones for 
cases and controls were estimated separately using the 
ARACNE algorithm [41, 42], as implemented in the 
R package bnlearn [43]. All measured hormone lev-
els (a total of nine) were considered nodes in the net-
work. To define the network parameters, let G =  (V, E) 
be a graph, with nodes (vertices) V and links (edges) E. 
Hence, a link between two nodes in the graph describes 
an association between the corresponding hormone lev-
els. Network parameters were computed for each of the 
nine nodes in the network using the R package igraph 
[44]. The degree of a node v ∈ V  is the number of links 
incident upon v , and we denote it CD(v) = deg (v). The 
closeness, CC(v), of v is the inverse of its farness, where 
the latter measures the sum of its distances to all other 
nodes. Betweenness, CB(v), measures the number of times 
the shortest path between two other nodes goes through 
v. Finally, the eigenvector centrality of each node, CE(v), 
was computed. These network parameters are defined 
for each node, but a global measure of the corresponding 
parameter for all nodes in the network can be also com-
puted using the concept of centralization. In other words, 
aggregate measures for an entire endocrine network can 
be found, as has previously been done for immune mark-
ers and described in detail elsewhere [45]. A bootstrap 
procedure was applied in order to estimate a confidence 
interval for each centralized network parameter. These 
centralized parameters were recomputed 10, 000 times 
on the networks estimated through subsampling, sepa-
rately for cases and controls. To ensure coherence of the 
whole procedure, the subsample size was held equal to 
the number of samples in each bootstrapping replication. 
The centralization measures were computed for each 
network estimated in each bootstrapping run, so that 
confidence intervals for the differences in centralized 
network parameters between cases and controls could be 
computed.
Fuite and co-workers reported that estimated endo-
crine networks for cases and controls can be similar in 
overall connectivity but visibly different in topology; i.e., 
that the distribution of centrality among the nodes within 
each network is markedly different [19]. This means that 
a global measure of centrality might not be a reliable 
parameter, and we therefore also analysed single node 
centrality across groups. We again performed bootstrap-
ping in order to derive an estimate of the variability and 
construct confidence intervals, and performed a t test 
to assess the significance of the across-group difference 
for each node. Finally, in order to explore the possible 
relationship between network characteristics and clini-
cal features, the single node degree centrality for CFS 
patients having Chalder fatigue score above or at median 
(median  =  20) were compared to those having score 
below median. Likewise, patients having steps/day above 
or at median (median =  4293) were compared to those 
below median.
Results
A total of 120 CFS patients and 68 healthy controls were 
included. CFS patients had significantly higher scores for 
depressive symptoms and fatigue, and lower number of 
steps per day as compared with healthy controls (Table 1). 
Gender, age, body mass index and menstrual characteris-
tics were similarly distributed in the two groups. In the 
CFS group, 75  % adhered to the Fukuda definition, and 
40 % adhered to the Canada 2003-definition.
CFS patients had significantly higher levels of 
plasma norepinephrine (p  <  0.001), plasma epineph-
rine (p  =  0.002) and plasma FT4 (p  =  0.008), and sig-
nificantly lower levels of urine cortisol/creatinine ratio 
(p  =  0.001) (Table  2). Urine norepinephrine/creatinine 
ratio was slightly higher in the CFS group. P values were 
not substantially affected when adjusting for the possible 
confounding effects of gender, age, BMI and depressive 
symptoms. Also, separate comparisons of the Fukuda- 
and Canada 2003-subgroups of CFS patients with healthy 
controls did not reveal any substantial effect of subgroup-
ing (Table 3).
In healthy controls, urine norepinephrine:creatinine 
was significantly associated with plasma norepineph-
rine in multivariate linear regression models (Table  4; 
Fig. 1a). In CFS patients, no such association was found. 
However, the CFS group displayed a weak association 
between urine epinephrine:creatinine and plasma epi-
nephrine which was not seen in healthy controls (Table 4; 
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Table 1 Background characteristics
CFS chronic fatigue syndrome, SD standard deviation, IQR interquartile range, n.a. not applicable
CFS patients Healthy controls P value
Count—no. 120 68
Gender—no. (%)
 Male 32 (27) 22 (32) 0.408
 Female 88 (73) 46 (68)
Ethnicity—no. (%)
 Scandinavian 118 (98) 62 (91) 0.027
 Not Scandinavian 2 (1.7) 6 (8.8)
Age—years, mean (SD) 15.4 (1.6) 15.1 (1.6) 0.179
Body mass index—kg/m2, mean (SD) 21.5 (4.2) 20.6 (3.7) 0.131
Experienced menarche (females only)—no. (%)
 No 11 (13) 5 (19) 0.411
 Yes 75 (87) 21 (81)
Days since last menstrual bleeding (females only)—median (IQR) 15 (15) 16 (14) 0.884
Disease duration—months, median (IQR) 18 (14) n.a. n.a.
Depressive symptom score—mean (SD) 17 (10) 6 (8) <0.001
Fatigue score—mean (SD) 19 (6) 9 (5) <0.001
Steps per day—mean (SD) 4662 (2386) 10,293 (3716) <0.001
Adherence to CDC diagnostic criteria—no. (%)
 No 29 (25) n.a. n.a.
 Yes 88 (75) n.a.
Adherence to Canada diagnostic criteria—no. (%)
 No 69 (60) n.a. n.a.
 Yes 46 (40) n.a.
Table 2 Hormone levels among CFS patients and healthy controls
Italic values indicate significance of p value (p < 0.05)
CFS chronic fatigue syndrome, SD standard deviation, IQR interquartile range, ACTH adrenocorticotrophic hormone, TSH thyroid stimulating hormone, FT4 free 
thyroxine
a Applying multivariate linear regression modelling. In order to obtain an approximate normal distribution for all dependent variables, urine 
norepinephrine:creatinine ratio and urine cortisol:creatinine ratio was ln-transformed, and three extreme outliers for plasma epinephrine were removed and replaced 
by imputed values




Plasma norepinephrine—mean (SD) 1981 (777) 1497 (418) <0.001 <0.001
Urine norepinephrine:creatinine ratio—median (IQR) 12.4 (5.8) 10.6 (5.8) 0.075 0.01
Plasma epinephrine—median (IQR) 308 (130) 267 (99) 0.002 <0.001
Urine epinephrine:creatinine ratio—median (IQR) 1.25 (1.22) 1.45 (0.99) 0.688 0.887
Plasma ACTH—median (IQR) 3.80 (2.70) 4.07 (2.90) 0.272 0.368
Plasma cortisol—mean (SD) 365 (145) 351 (149) 0.536 0.792
Urine cortisol:creatinine ratio—median (IQR) 3.45 (3.25) 5.34 (2.76) 0.001 0.002
Plasma TSH—mean (SD) 2.63 (1.08) 2.76 (1.43) 0.497 0.703
Plasma FT4—mean (SD) 15.4 (2.2) 14.6 (1.8) 0.008 0.015
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Fig.  1b). Also, in CFS patients, urine cortisol:creatinine 
was strongly associated with plasma cortisol, which in 
turn was associated with both plasma ACTH and plasma 
FT4 (Table 4; Fig. 1c). In healthy controls, there was no 
significant relationship between urine cortisol:creatinine 
and plasma cortisol. Furthermore, plasma cortisol was 
not associated with plasma FT4 and the association to 
plasma ACTH was attenuated as compared with the CFS 
group; instead, an association between plasma cortisol 
and plasma TSH was found.
Centralized network parameters were equal across 
the two groups (Table  5). However, all single hor-
mone degree centralities were significantly differ-
ent across groups (Table  6). Of particular interest, 
degree centrality for plasma norepinephrine and 
urine norepinephrine:creatinine was lower among 
CFS patients as compared with healthy controls, 
whereas degree centrality for plasma epinephrine, 
urine epinephrine:creatinine, plasma cortisol and urine 
cortisol:creatinine was highest in the CFS group (Table 6; 
Fig. 2).
Within the CFS group, single hormones were not asso-
ciated with clinical markers, except for a positive associa-
tion between urine cortisol:creatinine and steps per day 
(Table 7). However, as for degree centrality of single hor-
mones, the most disabled patients differed from the least 
disabled (Table 8). Of particular interest, plasma cortisol 
degree centrality was highest among those with the high-
est fatigue score and the lowest number of steps per day 
(Table 8; Fig. 3).
Discussion
The most important findings of this study are (a) That 
there are different interrelations between hormones of 
the HPA axis, the SAM system, and the thyroid system in 
CFS patients and healthy controls; and (b) That there is 
an association between hormone control characteristics 
and important clinical variables in the CFS group. Thus, 
based upon a complex statistical approach, the present 
study provide further evidence that altered neuroendo-
crine control mechanisms might be at the core of CFS 
pathophysiology.
A central characteristic of the previous documented 
attenuation of the HPA axis in CFS is reduced respon-
sivity, resulting in weakened cortisol response to com-
mon daily stressors (such as awakening), and a flattened 
cortisol diurnal curve [7]. On the other hand, increased 
responsivity is a hallmark of the sympathetic cardiovas-
cular control alterations in CFS, causing for instance 
an exaggerated heart rate and peripheral resistance 
response during orthostatic challenge [12, 14]. The pre-
sent results corroborate these previous observations. 
The plasma hormone concentrations are “snap-shots” 
from the different endocrine systems, whereas the urine 
Table 3 Hormone levels among subgroups of CFS patients as compared with healthy controls
Italic values indicate significance of p value (p < 0.05)














P value Fukuda 
vs healthy con-
trols
P value Canada 








12.4 (5.8) 12.3 (5.0) 13.1 (5.3) 10.6 (5.8) 0.088 0.029
Plasma epinephrine—
median (IQR)
308 (130) 309 (130) 304 (142) 267 (99) 0.004 0.019
Urine epinephrine:creatinine 
ratio—median (IQR)
1.25 (1.22) 1.23 (1.10) 1.27 (1.10) 1.45 (0.99) 0.466 0.789
Plasma ACTH—median (IQR) 3.80 (2.70) 3.70 (2.70) 4.35 (2.60) 4.07 (2.90) 0.272 0.822
Plasma cortisol—mean (SD) 365 (145) 360 (143) 383 (153) 351 (149) 0.726 0.268
Urine cortisol:creatinine 
ratio—median (IQR)
3.45 (3.25) 3.47 (3.30) 3.44 (2.80) 5.34 (2.76) 0.003 0.005
Plasma TSH—mean (SD) 2.63 (1.08) 2.48 (0.96) 2.67 (0.87) 2.76 (1.43) 0.17 0.695
Plasma FT4—mean (SD) 15.4 (2.2) 15.4 (2.3) 15.6 (2.5) 14.6 (1.8) 0.013 0.027
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hormone:creatinine ratios, analyzed in morning spot 
samples, might be seen as an integral of the endocrine 
activity during the preceding night. A linear association 
between plasma and urine level of the same hormone 
directly suggest low plasma variations, possibly explain-
ing the significant relationship among plasma cortisol 
and urine cortisol:creatinine in the CFS patients, as well 
as the significant relationship among plasma norepineph-
rine and urine norepinephrine:creatinine in the healthy 
controls.
Normally, plasma cortisol is controlled by plasma 
ACTH [46], explaining the linear relationship between 
Table 4 Relationship between selected markers of sympathetic and HPA activity, and other hormones
Multivariate linear regression models. The final mulitvariat linear regression models for each dependent variable in CFS patients and healthy controls, respectively, cf. 
Fig. 1
Italic values indicate significance of p value (p < 0.05)
CFS chronic fatigue syndrome, HPA hypothalamus–pituitary–adrenal, CI confidence interval, ACTH adrenocorticotrophic hormone, TSH thyroid stimulating hormone, 
FT4 free thyroxine
CFS patients Healthy controls
Dependent variable: plasma norepinephrine
 R squared 0.015 0.043
 Plasma epinephrine
  Regression coefficient, B (95 % CI) 0.82 (−0.38 to 2.02) 1.19 (−0.19 to 2.58)
  p value 0.179 0.090
Dependent variable: urine norepinephrine:creatinine ratio
 R squared 0.009 0.114
 Plasma norepinephrine
  Regression coefficient, B (95 % CI) 4.8 (−4.6 to 14) × 10−5 35 (11–59) × 10−5
  p value 0.314 0.005
Dependent variable: plasma epinephrine
 R squared 0.015 0.043
 Plasma norepinephrine
  Regression coefficient, B (95 % CI) 0.02 (−0.01 to 0.05) 0.04 (−0.01 to 0.08)
  p value 0.179 0.090
Dependent variable: urine epinephrine:creatinine ratio
 R squared 0.028 0.000
 Plasma epinephrine
  Regression coefficient, B (95 % CI) 88 (−7 to 182) × 10−5 −11 (−221 to 199) × 10−5
  p value 0.069 0.917
Dependent variable: plasma cortisol
 R squared 0.184 0.184
 Plasma ACTH
  Regression coefficient, B (95 % CI) 25.3 (13.4–37.2) 15.3 (1.1–29.6)
  p value <0.001 0.036
 Plasma TSH
  Regression coefficient, B (95 % CI) 12.7 (−9.4 to 35.0) 26.7 (1.1–52.4)
  p value 0.262 0.041
 Plasma FT4
  Regression coefficient, B (95 % CI) 17.0 (6.0–28.0) −4.9 (−24.2 to 14.4)
  p value 0.003 0.613
Dependent variable: urine cortisol:creatinine ratio
 R squared 0.058 0.016
 Plasma cortisol
  Regression coefficient, B (95 % CI) −11 (−19 to −3.0) × 10−4 −7 (−20 to 6.8) × 10−4
  p value 0.008 0.311
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Fig. 1 Results of multivariate linear regression modelling in CFS patients (left) and healthy controls (right). a Plasma norepinephrine and urine 
norepinephrine:creatinine as dependent variables. b Plasma epinephrine and urine epinephrine:creatinine as dependent variables. c Plasma cortisol 
and urine cortisol:creatinine as dependent variables. P plasma, U urine, Epi epinephrine, FT4 free thyroxine, ACTH adrenocorticotrophic hormone, 
TSH thyroid stimulating hormone, NorEpi norepinephrine, Cort cortisol, Creat creatinine
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these two hormones in CFS patients as well as controls. 
However, the regression coefficient is higher in CFS 
patients, and the interaction with thyroid hormones is 
strikingly different from the healthy control group, sug-
gesting an alteration in control mechanisms. The network 
analyses might be interpreted in the same way: The single 
hormone degree centrality among CFS patients suggests 
less variability and “tighter” control of the HPA axis, and 
more variability and “looser” control of the sympathetic 
nervous system, as compared to healthy controls.
On a general level, the findings in this study complies 
with the findings of Fuite and co-workers, who reported 
that adult CFS patients and healthy controls displayed 
quite similar centralized network parameters, but that 
there were significant differences in single node central-
ity indices [19]. However, Fuite and co-wokers found a 
decrease in plasma cortisol and an increase in plasma 
norepinephrine degree centrality, as opposed to the pre-
sent results. The reasons for these discrepancies are not 
clear; however, results are not necessarily comparable 
across the two studies, as the total number of nodes in 
the network analyses was largely different.
Within the CFS group, important clinical variables are 
associated with network parameters but not with single 
hormone levels. These findings seem to suggest that the 
underlying disease mechanisms of CFS are more related 
Table 5 Centralized network parameters among  CFS 
patients and healthy controls





95 % CI (CFS 
patients—
healthy controls)
Betweenness centrality 0.49 0.61 (−0.29 to 0.46)
Closeness centrality 0.44 0.54 (−0.23 to 0.35)
Degree centrality 0.64 0.69 (−0.39 to 0.50)
Eigenvector centrality 0.50 0.58 (−0.22 to 0.31)
Table 6 Single hormone degree centrality (DC) among CFS patients and healthy controls
Italic values indicate significance of p value (p < 0.05)
CFS chronic fatigue syndrome, CI confidence interval, ACTH adrenocorticotrophic hormone, TSH thyroid stimulating hormone, FT4 free thyroxine
* t test
CFS patients Healthy controls Difference in DC (95 % CI, CFS patients—healthy controls) p value*
Plasma norepinephrine 0.36 0.44 −0.09 (−0.15 to −0.03) 0.003
Urine norepinephrine:creatinine ratio 0.49 1.00 −0.51 (−0.57 to −0.44) <0.001
Plasma epinephrine 0.59 0.17 0.42 (0.36–0.48) <0.001
Urine epinephrine:creatinine ratio 0.72 0.38 0.34 (0.28–0.40) <0.001
Plasma ACTH 0.54 0.55 −0.02 (−0.08 to 0.04) 0.572
Plasma cortisol 0.78 0.46 0.33 (0.26–0.39) <0.001
Urine cortisol:creatinine ratio 1.00 0.63 0.37 (0.31–0.43) <0.001
Plasma TSH 0.36 0.65 −0.29 (−0.35 to −0.24) <0.001
Plasma FT4 0.67 0.63 0.04 (−0.02 to 0.10) 0.231
















Fig. 2 Results of network analyses (single node diagrams) in CFS 
patients (left) and healthy controls (right). a Plasma norepinephrine as 
single node. b Plasma epinephrine as single node. c Plasma cortisol 
as single node. P plasma, U urine, Epi epinephrine, FT4 free thyrox-
ine, ACTH adrenocorticotrophic hormone, TSH thyroid stimulating 
hormone, NorEpi norepinephrine, Creat creatinine
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to altered neuroendocrine control than to altered hor-
mone levels per se. Plasma cortisol degree centrality is 
of particular interest: Here, the least disabled group of 
patients are more similar to healthy controls than the 
most disabled group. This observation is in line with 
other reports linking altered HPA axis physiology to 
Table 7 Association between single hormones and clinical markers in CFS patients—correlation and regression analyses
Italic values indicate significance of p value (p < 0.05)
















−0.061 −0.078 −0.001 −0.034 −0.002 −0.005




−0.071 −0.105 −1.43 0.096 0.152 871




−0.075 −0.156 −0.008 0.089 0.117 2.35




−0.048 −0.093 −0.885 −0.001 0.011 42




−0.045 −0.066 −0.003 −0.078 −0.081 −1.27




0.018 0.057 0.358 0.082 0.242 743
 P value 0.785 0.540 0.666 0.190 0.006 0.022
Table 8 Single hormone degree centrality (DC) among the most and the least disabled patients
Fatigue score (left) and steps per day (right)
Italic values indicate significance of p value (p < 0.05)
CFS chronic fatigue syndrome, CI confidence interval, DC degree centrality
* t test





Difference in DC  
(95 % CI, high–low)







Plasma norepinephrine 0.80 0.48 0.32 (0.25–0.39) <0.001 0.45 0.50 −0.05 (−0.12 to 0.02) 0.140
Urine norepinephrine: 
creatinine ratio
0.80 0.63 0.17 (0.10–0.25) <0.001 0.89 0.50 0.39 (0.32–0.47) <0.001
Plasma epinephrine 0.45 0.48 −0.04 (−0.11 to 0.04) 0.332 0.45 0.50 −0.05 (−0.12 to 0.02) 0.145
Urine epinephrine: 
creatinine ratio
0.45 0.48 −0.04 (−0.12 to 0.05) 0.381 1.00 1.00 0.00 (−0.07 to 0.07) 1.000
Plasma cortisol 1.00 0.30 0.70 (0.62–0.77) <0.001 1.00 0.50 0.50 (0.43–0.57) <0.001
Urine cortisol: 
creatinine ratio
1.00 1.00 0.00 (−0.08 to 0.08) 1.000 0.89 1.00 −0.11 (−0.17 to −0.04) 0.003
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symptoms and function [9, 11]. Further research should 
aim at uncover the underlying mechanisms; one promis-
ing field of study might be epigenetic alterations of the 
glucocorticoid receptor gene [47].
Taken together, the findings of this study comply with 
the “sustained arousal” model of CFS [17]. In this model, 
a maladaptive stress response is considered a central 
pathophysiological element, eliciting autonomic and neu-
roendocrine alterations that parallel the pathophysiology 
of chronic post-traumatic stress disorder (PTSD). Inter-
estingly, the combination of HPA attenuation and SAM 
enhancement seem to be a central characteristic of PTSD 
[48].
Study strengths and limitations
This study is based upon a large and well-characterized 
cohort of adolescent CFS, and applies state-of-the-art 
statistical methods to explore complex interactions 
among several variables. We did not apply dynamic test-
ing, such as CRH stimulation test or dexamethasone sup-
pression test. Such testing might have yielded increased 
insight into neuroendocrine control mechanisms, and 
might also have provided validation of the network analy-
ses. Our wide inclusion criteria might possibly obscure 
important differences across subgroups; however, sub-
grouping according to stricter diagnostic definitions 
did not reveal differential effects. Although the different 
methods used in this study in general have well-estab-
lished reliability and validity, these properties have hardly 
been specifically explored in adolescent CFS patient, and 
the design did not allow us to do so in the present study 
either.
Conclusion
This study reveals different interrelation between hor-
mones of the HPA axis, the SAM system, and the thy-
roid system in CFS patients and healthy controls, and 
an association between hormone control characteris-
tics and important clinical variables in the CFS group. 
These results add to the growing insight of CFS disease 
mechanisms.
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